Loading
A phase 2 trial of TRK-950 and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Toray Industries, Inc, now recruiting.
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer is a phase 2 interventional study registered as NCT06038578 by Toray Industries, Inc, with 146 participants planned, started 2023-10-04 and due to reach its primary completion in 2026-06-30. Interventions recorded: TRK-950, Ramucirumab and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ramucirumab, Anti-angiogenic therapy, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Anti-angiogenic therapy, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/